Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings,

Inc. March 28, 2019 Shareholder Update

NewswireMarch 28, 2019

28, 2019 /PRNewswire/ -- (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its activities:

activities: As previously reported, we are continuing marketing to physicians across the United States. Since our last shareholder

update several physicians have joined CaverStem and are in the process of training and patient acquisition.

We have added physicians

in Hawaii, California, Ohio, Texas and Tennessee. We will continually add the new physicians to the

CaverStem website, begin the patient awareness campaign in each area and schedule physician training.

These physicians came

to us through our physician marketing program as previously disclosed. We are continuing to use this marketing tool with mailers

and emails with follow up personal or telephone communication with physicians across the country.

We are always working

to get physicians trained as soon as possible. In order to properly train each physician, we require a minimum of 5 patients. This

requires scheduling all patients, the physician and our trainer. This process has caused delays, therefore we have added additional

medical personnel to travel to each physicians office to train. With this increased flexibility on our part we anticipate a reduction

As previously disclosed,

our patient marketing campaign has relied heavily on social media with the use of Google Ad Words and banner advertising. We believe

social media is a great resource as 80% of patients find us, using their phones and tablets. In order to continue to grow patient

awareness print advertising is now being used and we are continuing to develop our television commercial which will be edited to

direct patients to each physician in their area.

CaverStem International:

We have successfully treated our first six patients in Italy and other patients are scheduled. Due to the increased international

demand and to compliment our existing relationship with Scott Shea, CEO of Aspire Medical in Munich, Germany with

whom we enjoy a phenomenal relationship, Thomas Bianchi has joined the company as our international sales representative.

Mr. Bianchi has decades long experience in medical device sales, having worked for companies such as Stryker and Medtronics.

With Scott and Thomas on the CaverStem team we expect to continue to grow our international physician base not

only in recruiting new physicians but in more effectively servicing existing physicians.

Progress in Russia has

been much slower than expected. Government exemptions are required for the ongoing import of our device. This is a slow and tedious

process in getting approval, therefore our progress has been delayed. We will continue with this process and maintain great faith

in our relationship with Promo Med and our expansion in to this sizable market.

trial: As we've previously advised, we are working on our paper for publication. This is ongoing and in compliance with our contractual

obligations. Once our paper has been approved by The Journal of Translational Medicine and a publication date advised we will advise.

Additionally, we have

designed an electronic patient registry that is intended to include data from our clinical trial, data from treating physicians

using centrifuge technology with a 30cc to 60cc bone marrow aspiration and our second generation, needle only, mini bone

marrow aspiration technology drawing a maximum of 20cc of bone marrow. Recent publications have disclosed that with the second

generation needle technology a larger amount of pure cell product is harvested because of a reduction in dilution of blood, thus

requiring a reduced bone marrow aspiration. The registry will enable the company to gather and maintain ongoing HIPAA compliant

information on patient demographics, history and treatment progress. Patient names and addresses will not be included on the registry

or disclosed to the company.

We have received positive

feedback from treating physicians of a 70% to 90% efficacy in their patients. Obviously results differ depending on the age and

health of the patient and cause and severity of their erectile dysfunction.

previously announced, we are progressing with the development of the FemCelz procedure for the treatment of female